Meeting
2022 ASCO Annual Meeting
Monitoring efficacy of neoadjuvant sunitinib in metastatic renal cell carcinoma using a personalized and tumor informed ctDNA assay.
Authors
Christine B. Peterson
University of Texas MD Anderson Cancer Center, Houston, TX
Christine B. Peterson , Ekaterina Kalashnikova , Jordan Feeney , Allyson Koyen Malashevich , Himanshu Sethi , Alexey Aleshin , Eric Jonasch
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Biologic Correlates
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4525)
DOI
10.1200/JCO.2022.40.16_suppl.4525
Abstract #
4525
Poster Bd #
16
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: Final results of the noninterventional change study.
First Author: Peter J. Goebell
Poster
2014 Genitourinary Cancers Symposium
Interpreting first-line options in mRCC: A look into the German RCC-registry.
First Author: Peter J. Goebell
Poster
2011 ASCO Annual Meeting
Observation prior to systemic therapy in patients with metastatic renal cell carcinoma in the kinase inhibitor era.
First Author: R. A. Fisher
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.
First Author: Ana-Alicia Beltran-Bless